US · TNXP
Tonix Pharmaceuticals Holding Corp.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Chatham, NJ 07928
- Website
- tonixpharma.com
Price · as of 2024-12-31
$13.60
Market cap 178.65M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $13.75 | +1.1% |
| Intrinsic Value(DCF) | $5.21 | -61.69% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $4,224,000,000.00 | ||||
| 2013 | $8,678,400,000.00 | ||||
| 2014 | $4,544,000,000.00 | ||||
| 2015 | $1,472,000,000.00 | ||||
| 2016 | $313,600,000.00 | ||||
| 2017 | $229,120,000.00 | ||||
| 2018 | $17,920,000.00 | ||||
| 2019 | $659,200.00 | ||||
| 2020 | $812,800.00 | ||||
| 2021 | $140,800.00 | ||||
| 2022 | $12,400.00 | ||||
| 2023 | $1,184.00 | ||||
| 2024 | $13.02 | $13.75 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Tonix Pharmaceuticals Holding Corp.'s (TNXP) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $13.75
- Current price
- $13.60
- AI upside
- +1.1%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.21
-61.69% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TNXP | Tonix Pharmaceuticals Hol… | $13.60 | 178.65M | +1% | -62% | — | — | -0.23 | 0.21 | 2.92 | 0.86 | — | 0.21 | 23.07% | -1354.28% | -1288.25% | -106.12% | -200.34% | -81.95% | 0.04 | — | 6.50 | 5.83 | 1.26 | -9723.00% | 2994.00% | -4445.00% | -207.14% | -3.33 | -89.46% | 0.00% | 0.00% | 265.83% | 0.47 | 1.05 | -6.34 | -7.49 |
| APLT | Applied Therapeutics, Inc… | $0.10 | 14.86M | +30,191% | +123% | — | +60,988% | -0.76 | 1.40 | 175.54 | -0.03 | — | 1.40 | 100.00% | -22922.86% | -23214.07% | -529.97% | 242.94% | -149.27% | 0.05 | — | 3.06 | 2.91 | 0.74 | -4648.00% | -9545.00% | 5280.00% | -105.55% | -3.09 | 196.37% | 0.00% | 0.00% | 34.41% | -0.03 | -0.04 | 7.18 | -10.84 |
| AVTX | Avalo Therapeutics, Inc. | $17.50 | 197.65M | -16% | -59% | — | +1,518% | -1.80 | 0.47 | 143.03 | 1.04 | — | 0.51 | 182.99% | -15535.60% | -7965.76% | -50.06% | 26350.77% | -40.91% | 0.00 | — | 19.96 | 19.42 | 1.96 | -9713.00% | -7708.00% | 5908.00% | -77.77% | -7.05 | 18867.69% | 0.00% | 0.00% | 201.50% | 1.03 | 1.45 | -160.77 | -1.75 |
| ELDN | Eledon Pharmaceuticals, I… | $2.62 | 157.07M | — | — | — | — | -5.08 | 1.56 | — | -1.26 | — | 2.15 | 0.00% | — | — | -57.73% | 218.52% | -27.16% | 0.01 | — | 12.42 | 12.11 | 0.55 | -5427.00% | — | 1959.00% | -25.69% | -4.08 | 146.36% | 0.00% | 0.00% | 8.35% | -0.63 | -0.95 | — | -1.36 |
| ELTX | Elicio Therapeutics, Inc. | $12.99 | 224.19M | — | — | — | — | -1.86 | -8.51 | — | -2.08 | — | -8.51 | 0.00% | — | — | -170157.38% | -3590.26% | -187.61% | -2.30 | -98.87 | 1.80 | 1.53 | -0.17 | -3894.00% | — | 1342.00% | -38.59% | -3.22 | -2965.28% | 0.00% | 0.00% | 0.00% | -2.33 | -2.82 | — | -13.06 |
| FATE | Fate Therapeutics, Inc. | $1.48 | 170.72M | +1,664% | -45% | — | +3,067% | -1.31 | 0.86 | 26.81 | -0.41 | — | 0.86 | -94.12% | -2222.45% | -2051.08% | -51.84% | -143.19% | -35.89% | 0.38 | — | 5.79 | 5.67 | -0.25 | -2988.00% | -5124.00% | -936.00% | -62.88% | -2.94 | -108.62% | 0.00% | 0.00% | 10.10% | -0.35 | -0.47 | 7.88 | -6.64 |
| FBRX | Forte Biosciences, Inc. | $30.22 | 378.56M | — | — | — | — | -0.53 | 0.36 | — | 1.11 | — | 0.36 | 0.00% | — | — | -80.82% | 951.20% | -70.57% | 0.00 | — | 6.76 | 6.43 | 0.63 | -5116.00% | — | 690.00% | -162.41% | -3.39 | 799.95% | 0.00% | 0.00% | 54.26% | 1.08 | 1.28 | — | -3.19 |
| IPHA | Innate Pharma S.A. | $1.72 | 160.74M | +2,263% | -50% | — | +2,571% | -2.98 | 16.70 | 11.69 | -2.08 | -0.52 | 16.70 | 100.00% | -408.64% | -391.97% | -162.91% | 247.94% | -34.57% | 3.51 | -91.12 | 2.60 | 2.50 | 0.75 | 57778.00% | -7568.00% | -7913.00% | -4.94% | -0.21 | 35.03% | 0.00% | 0.00% | 3.18% | -1.90 | -13.41 | 7.74 | -4.85 |
| MCRB | Seres Therapeutics, Inc. | $8.74 | 79.07M | — | — | — | — | 875.27 | 8.64 | — | -1.50 | 14208.58 | 8.64 | 0.00% | — | — | -0.88% | -241.20% | 0.05% | 6.65 | — | 0.94 | 0.86 | -0.51 | 616.00% | — | 1888.00% | -125.16% | -3.61 | -296.22% | 0.00% | 0.00% | 8.38% | -1.48 | -1.21 | — | -12.11 |
| MIST | Milestone Pharmaceuticals… | $1.71 | 145.64M | +1,960% | — | — | — | -2.76 | 8.71 | — | -2.63 | — | 8.71 | 0.00% | — | — | -277.55% | -10631.82% | -55.09% | 4.17 | 11.76 | 9.10 | 8.87 | -0.78 | -5180.00% | -10000.00% | -3794.00% | -25.23% | -3.55 | -7293.18% | 0.00% | 0.00% | 7.45% | -2.36 | -3.45 | — | -6.51 |
| NKTX | Nkarta, Inc. | $2.70 | 191.78M | — | — | — | — | -1.15 | 0.31 | — | 0.52 | — | 0.31 | 0.00% | — | — | -31.94% | -76.69% | -24.72% | 0.20 | — | 14.45 | 14.14 | -0.44 | -3333.00% | — | -893.00% | -83.37% | -5.27 | -62.28% | 0.00% | 0.00% | 3.92% | 0.49 | 0.60 | — | -0.95 |
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
- CEO
- Seth Lederman
- Employees
- 81
- Beta
- 1.87
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.21 ÷ $13.60) − 1 = -61.69% (DCF, example).